A Phase 3 interventional study of Teduglutide and Standard Medical Therapy in Short Bowel Syndrome, sponsored by Shire. Completed at 8 sites in 4 countries. Open to participants aged 4 Months to 12 Months. Per ClinicalTrials.gov, last updated 2021-05-11.
Sponsored by Shire (part of Takeda) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 20 studies testing teduglutide in Short Bowel Syndrome — 1 open to participants now, 2 under way, 1 of them phase 3. teduglutide · Short Bowel Syndrome.
Among the 20 studies testing teduglutide in Short Bowel Syndrome, this one is the 15th largest by enrollment, is one of 4 that started in 2018, is one of 16 in phase 3, and was the 14th registered.
159 studies on the registry are indexed under Short Bowel Syndrome; 24 are open to participants now.
Browse Short Bowel Syndrome studies →1 of the 20 studies testing teduglutide in Short Bowel Syndrome is open now, in 1 country. Recruiting first, the newest first:
Meyer Children's Hospital IRCCS · Sites in Italy
Ages 4 mo–17 yrs
By country, each count listing its studies:
teduglutide: first FDA approval 2012 (GATTEX KIT), first EMA approval 2012. What it is approved for, and how studies give it, is on its page →
Of the 18 Short Bowel Syndrome studies recruiting now, 8 (44%) set no upper age limit and 8 (44%) stop at 75 or younger; 9 take children under 18; 2 take healthy volunteers.
This study: 4 Months to 12 Months · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
20 studies; the count open now beside each. This study's row is marked.
First in 2004; this study’s year is marked. 4 started in 2018.
This study's enrollment of 10 is below the median of 21 across 108 interventional studies indexed under Short Bowel Syndrome.
Median enrollment 20 across the 20 interventional studies. Of the 18 that completed or were terminated, 16 (89%) have results posted.
This tab as a report to print or save as PDF → With an account.
17 of 20 have an industry lead sponsor. The 6 most frequent:
This study is registered under Shire, one of the names counted as Takeda. Under that name alone:
Shire is the lead sponsor of 351 studies on the registry; 2 are open to participants now.
Of its 48 completed or terminated interventional studies of FDA-regulated products, 48 (100%) have results posted.
26 studies in Short Bowel Syndrome by Takeda: 1 open now, 3 under way, 1 of them phase 3. Of 23 finished, 16 (70%) have results posted.
Among the 26 studies in Short Bowel Syndrome by Takeda, this one is the 14th largest by enrollment of the 18 interventional ones that give a count, is one of 3 that started in 2018, is one of 17 in phase 3, and was the 15th registered.
Takeda’s Short Bowel Syndrome studies by the year they started, since 2004.
1 of the studies testing teduglutide in Short Bowel Syndrome that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06973304Phase 3TakedaA Study of Teduglutide in Chinese Adults With Short Bowel Syndrome | 2027-02-10 |
Add it to your calendar (.ics) → With an account.
Among the 20 studies testing teduglutide in Short Bowel Syndrome, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Takeda’s 26 in Short Bowel Syndrome:
This tab as a report to print or save as PDF → With an account.
The purpose of the study is to evaluate the safety, efficacy/pharmacodynamics (PD) and pharmacokinetics (PK) of teduglutide treatment in infants with short bowel syndrome (SBS) dependent on parenteral (PN) support.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Severe hepatic dysfunction or portal hypertension, defined by at least 2 of the following parameters:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
INR, PT and aPTT (clotting tests)
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive 0.05 milligram per kilogram (mg/kg) subcutaneous (SC) injection of teduglutide into abdomen or into either the thigh or arm once daily (QD) in addition to standard medical therapy for 24 weeks.
Drug: Teduglutide · Other: Standard Medical Therapy · Device: Syringe · Device: Needle
Participants will receive standard medical therapy for 24 weeks.
Other: Standard Medical Therapy · Device: Syringe · Device: Needle
SC injection of 0.05 mg/kg teduglutide will be administered QD into abdomen or into either the thigh or arm for 24 weeks.
Standard medical therapy will be administered for 24 weeks.
Teduglutide will be administered using syringe (510k number: K980987).
Teduglutide will be administered using needle (510k number: K021475).
Number of Participants Who Achieved At Least 20 Percent (%) Reduction From Baseline in Weight-normalized Parenteral Support (PS) Volume at End of Treatment/Early Termination (EOT/ET)
Number of participants who achieved at least 20% reduction from baseline in weight-normalized PS volume at EOT/ET (up to Week 24) were reported. EOT/ET was defined as the last available visit after the date of first dose (or randomization in standard of care treatment group) during the 24-week treatment period.
Time frame: Baseline, EOT/ET (up to Week 24)
Plasma Concentration of Teduglutide at Nominal Time Points (Baseline at Pre-dose, and 1 Hour and 4 Hours Post-dose; 2 Hours Post-dose at Week 7)
Mean plasma concentration of teduglutide was reported.
Time frame: Baseline: Pre-dose,1, 4 hours post-dose, and 2 hours post-dose at Week 7
Number of Participants With Treatment-emergent Adverse Events (TEAEs)
An adverse event (AE) was any untoward medical occurrence in a clinical investigation participant administered a pharmaceutical product and that does not necessarily have a causal relationship with this treatment. TEAEs are defined as AEs that start or deteriorate on or after the date of the first dose of investigational product.
Time frame: From start of study treatment up to end of study (EOS) (up to Week 28)
Change From Baseline in Body Weight Z-score at Week 24
Body weight was measured using Z-score. Z-score was calculated as (observed value - median value of the reference population)/standard deviation value of reference population. A negative Z-score indicates values lower than the mean while a positive Z-score indicates values higher than the mean. Change from baseline in body weight Z-score at Week 24 was reported.
Time frame: Baseline, Week 24
Change From Baseline in Length Z-Score at Week 24
Length was measured using Z-score. Z-score was calculated as (observed value - median value of the reference population)/standard deviation value of reference population. A negative Z-score indicates values lower than the mean while a positive Z-score indicates values higher than the mean. Change from baseline in length Z-score at Week 24 was reported.
Time frame: Baseline, Week 24
Change From Baseline in Head Circumference Z-Score at Week 24
Head circumference was measured using Z-score. Z-score was calculated as (observed value - median value of the reference population)/standard deviation value of reference population. A negative Z-score indicates values lower than the mean while a positive Z-score indicates values higher than the mean. Change from baseline in head circumference Z-score at Week 24 was reported.
Time frame: Baseline, Week 24
Change From Baseline in Weight-for-Length Z-Score at Week 24
Weight-for-length was measured using Z-score. Z-score was calculated as (observed value - median value of the reference population)/standard deviation value of reference population. A negative Z-score indicates values lower than the mean while a positive Z-score indicates values higher than the mean. Change from baseline in weight-for-length Z-score at Week 24 was reported.
Time frame: Baseline, Week 24
Change From Baseline in Average Total Urine Output at Week 24
Average total urine output was recorded over a 48-hour period of nutritional stability at Week 24 was reported. Here, milliliter per kilogram per day is abbreviated as mL/kg/day.
Time frame: Baseline, Week 24
Change From Baseline in Fecal Output at Week 24
Change from baseline in the fecal output (average number of stools per day) at Week 24 was reported.
Time frame: Baseline, Week 24
Number of Participants With Positive Specific Antibodies to Teduglutide
Number of participants with positive specific antibodies to teduglutide were used to summarize the presence of antibodies.
Time frame: Baseline, EOS (up to week 28)
Number of Participants Who Achieved At Least 20 Percent (%) Reduction From Baseline in Weight-normalized Parenteral Support (PS) Caloric Intake at End of Treatment/Early Termination (EOT/ET)
Number of participants who achieved at least 20% reduction from baseline in weight-normalized PS caloric intake at EOT/ET (up to Week 24) were reported. EOT/ET was defined as the last available visit after the date of first dose (or randomization in standard of care treatment group) during the 24-week treatment period.
Time frame: Baseline, EOT/ET (up to Week 24)
Number of Participants Who Achieved 100 Percent (%) Reduction in Complete Weaning Off (Enteral Autonomy) Parenteral Support (PS) Volume at Week 24
Number of participants who achieved 100% reduction in complete weaning off (enteral autonomy) PS volume at Week 24 were reported.
Time frame: Week 24
Number of Participants Who Achieved 100 Percent (%) Reduction in Complete Weaning Off (Enteral Autonomy) Parenteral Support (PS) Volume at End of Study (EOS)
Number of participants who achieved 100% reduction in complete weaning off (enteral autonomy) PS volume at EOS (up to Week 28) were reported.
Time frame: EOS (up to Week 28)
Change From Baseline in Weight-normalized Parenteral Support (PS) Volume at End of Treatment/Early Termination (EOT/ET)
Change from baseline in weight-normalized PS volume at EOT/ET (up to Week 24) was reported. EOT/ET was defined as the last available visit after the date of first dose (or randomization in standard of care treatment group) during the 24-week treatment period.
Time frame: Baseline, EOT/ET (up to Week 24)
Percent Change From Baseline in Weight-normalized Parenteral Support (PS) Volume at End of Treatment/Early Termination (EOT/ET)
Percent change from baseline in weight-normalized PS volume at EOT/ET (up to Week 24) was reported. EOT/ET was defined as the last available visit after the date of first dose (or randomization in standard of care treatment group) during the 24-week treatment period.
Time frame: Baseline, EOT/ET (up to Week 24)
Change From Baseline in Weight-normalized Parenteral Support (PS) Caloric Intake at End of Treatment/Early Termination (EOT/ET)
Change from baseline in weight-normalized PS caloric intake at EOT/ET (up to Week 24) were reported. EOT/ET was defined as the last available visit after the date of first dose (or randomization in standard of care treatment group) during the 24-week treatment period. Here, kilo-calories per kilogram per day was abbreviated as (kcal/kg/day).
Time frame: Baseline, EOT/ET (up to Week 24)
Percent Change From Baseline in Weight-normalized Parenteral Support (PS) Caloric Intake at End of Treatment/Early Termination (EOT/ET)
Percent change from baseline in weight-normalized PS caloric intake at EOT/ET (up to Week 24) were reported. EOT/ET was defined as the last available visit after the date of first dose (or randomization in standard of care treatment group) during the 24-week treatment period.
Time frame: Baseline, EOT/ET (up to Week 24)
Change From Baseline in Weight-normalized Enteral Nutrition (EN) Volume at End of Treatment/Early Termination (EOT/ET)
Change from baseline in weight-normalized EN volume at EOT/ET (up to Week 24) was reported. EOT/ET was defined as the last available visit after the date of first dose (or randomization in standard of care treatment group) during the 24-week treatment period.
Time frame: Baseline, EOT/ET (up to Week 24)
Percent Change From Baseline in Weight-normalized Enteral Nutrition (EN) Volume at End of Treatment/Early Termination (EOT/ET)
Percent change from baseline in weight-normalized EN volume at EOT/ET (up to Week 24) was reported. EOT/ET was defined as the last available visit after the date of first dose (or randomization in standard of care treatment group) during the 24-week treatment period.
Time frame: Baseline, EOT/ET (up to Week 24)
Change From Baseline in Weight-normalized Enteral Nutrition (EN) Caloric Intake at End of Treatment/Early Termination (EOT/ET)
Change from baseline in weight-normalized EN caloric intake at EOT/ET (up to Week 24) were reported. EOT/ET was defined as the last available visit after the date of first dose (or randomization in standard of care treatment group) during the 24-week treatment period.
Time frame: Baseline, EOT/ET (up to Week 24)
Percent Change From Baseline in Weight-normalized Enteral Nutrition (EN) Caloric Intake at End of Treatment/Early Termination (EOT/ET)
Percent change from baseline in weight-normalized EN caloric intake at EOT/ET (up to Week 24) were reported. EOT/ET was defined as the last available visit after the date of first dose (or randomization in standard of care treatment group) during the 24-week treatment period.
Time frame: Baseline, EOT/ET (up to Week 24)
Number of Participants Who Achieved At Least 20 Percent (%) Increase From Baseline in Weight-normalized Enteral Nutrition (EN) Volume at End of Treatment/Early Termination (EOT/ET)
Number of participants who achieved at least 20% increase from baseline in weight-normalized EN volume at EOT/ET was reported. EOT/ET was defined as the last available visit after the date of first dose (or randomization in standard of care treatment group) during the 24-week treatment period.
Time frame: Baseline, EOT/ET (up to Week 24)
Number of Participants Who Achieved At Least 20 Percent (%) Increase From Baseline in Weight-normalized Enteral Nutrition (EN) Caloric Intake at End of Treatment/Early Termination (EOT/ET)
Number of participants who achieved at least 20% increase from baseline in weight-normalized EN caloric intake at EOT/ET was reported. EOT/ET was defined as the last available visit after the date of first dose (or randomization in standard of care treatment group) during the 24-week treatment period.
Time frame: Baseline, EOT/ET (up to Week 24)
The study was conducted at Finland and United Kingdom between 31 August 2018 (first participant first visit) and 24 September 2020 (last participant last visit).
| Milestone | Teduglutide (TED) | Standard of Care (SOC) |
|---|---|---|
| Started | 5 | 5 |
| Completed | 4 | 4 |
| Not completed | 1 | 1 |
| Withdrew: Severe diarrhea | 1 | 0 |
| Withdrew: Withdrawal by subject | 0 | 1 |
Number of participants who achieved at least 20% reduction from baseline in weight-normalized PS volume at EOT/ET (up to Week 24) were reported. EOT/ET was defined as the last available visit after the date of first dose (or randomization in standard of care treatment group) during the 24-week treatment period.
| Participants | Teduglutide (TED) | Standard of Care (SOC) |
|---|---|---|
| Diary Data: EOT/ET | 3 | 1 |
| Prescribed Data: EOT/ET | 3 | 3 |
Mean plasma concentration of teduglutide was reported.
| Nanogram per milliliter (ng/mL) | Teduglutide (TED) |
|---|---|
| Baseline: At Pre-dose | 0.00 (0.00 to 0.00) |
| Baseline: At 1 hour | 16.300 (7.25 to 25.70) |
| Baseline: At 4 hours | 8.385 (3.86 to 22.5) |
| Week 7: At 2 hours | 16.950 (14.80 to 19.10) |
An adverse event (AE) was any untoward medical occurrence in a clinical investigation participant administered a pharmaceutical product and that does not necessarily have a causal relationship with this treatment. TEAEs are defined as AEs that start or deteriorate on or after the date of the first dose of investigational product.
| Participants | Teduglutide (TED) | Standard of Care (SOC) |
|---|---|---|
| Number of Participants With Treatment-emergent Adverse Events (TEAEs) | 5 | 5 |
Body weight was measured using Z-score. Z-score was calculated as (observed value - median value of the reference population)/standard deviation value of reference population. A negative Z-score indicates values lower than the mean while a positive Z-score indicates values higher than the mean. Change from baseline in body weight Z-score at Week 24 was reported.
| Z-score | Teduglutide (TED) | Standard of Care (SOC) |
|---|---|---|
| Change From Baseline in Body Weight Z-score at Week 24 | -0.408 ± 0.377 | -0.289 ± 0.278 |
Length was measured using Z-score. Z-score was calculated as (observed value - median value of the reference population)/standard deviation value of reference population. A negative Z-score indicates values lower than the mean while a positive Z-score indicates values higher than the mean. Change from baseline in length Z-score at Week 24 was reported.
| Z-Score | Teduglutide (TED) | Standard of Care (SOC) |
|---|---|---|
| Change From Baseline in Length Z-Score at Week 24 | -0.274 ± 1.258 | -0.422 ± 0.384 |
Head circumference was measured using Z-score. Z-score was calculated as (observed value - median value of the reference population)/standard deviation value of reference population. A negative Z-score indicates values lower than the mean while a positive Z-score indicates values higher than the mean. Change from baseline in head circumference Z-score at Week 24 was reported.
| Z-Score | Teduglutide (TED) | Standard of Care (SOC) |
|---|---|---|
| Change From Baseline in Head Circumference Z-Score at Week 24 | -0.544 ± 0.446 | -0.167 ± 0.690 |
Weight-for-length was measured using Z-score. Z-score was calculated as (observed value - median value of the reference population)/standard deviation value of reference population. A negative Z-score indicates values lower than the mean while a positive Z-score indicates values higher than the mean. Change from baseline in weight-for-length Z-score at Week 24 was reported.
| Z-Score | Teduglutide (TED) | Standard of Care (SOC) |
|---|---|---|
| Change From Baseline in Weight-for-Length Z-Score at Week 24 | -0.447 ± 1.042 | -0.058 ± 0.992 |
Average total urine output was recorded over a 48-hour period of nutritional stability at Week 24 was reported. Here, milliliter per kilogram per day is abbreviated as mL/kg/day.
| mL/kg/day | Teduglutide (TED) | Standard of Care (SOC) |
|---|---|---|
| Change From Baseline in Average Total Urine Output at Week 24 | -0.61 ± 14.548 | 10.25 ± 17.383 |
Change from baseline in the fecal output (average number of stools per day) at Week 24 was reported.
| Average number of stools per day | Teduglutide (TED) | Standard of Care (SOC) |
|---|---|---|
| Change From Baseline in Fecal Output at Week 24 | -3.33 ± 3.547 | 1.67 ± 1.756 |
Number of participants with positive specific antibodies to teduglutide were used to summarize the presence of antibodies.
| Participants | Teduglutide (TED) |
|---|---|
| Number of Participants With Positive Specific Antibodies to Teduglutide | 0 |
Number of participants who achieved at least 20% reduction from baseline in weight-normalized PS caloric intake at EOT/ET (up to Week 24) were reported. EOT/ET was defined as the last available visit after the date of first dose (or randomization in standard of care treatment group) during the 24-week treatment period.
| Participants | Teduglutide (TED) | Standard of Care (SOC) |
|---|---|---|
| Diary Data: EOT/ET | 3 | 1 |
| Prescribed Data: EOT/ET | 3 | 3 |
Number of participants who achieved 100% reduction in complete weaning off (enteral autonomy) PS volume at Week 24 were reported.
| Participants | Teduglutide (TED) | Standard of Care (SOC) |
|---|---|---|
| Number of Participants Who Achieved 100 Percent (%) Reduction in Complete Weaning Off (Enteral Autonomy) Parenteral Support (PS) Volume at Week 24 | 0 | 0 |
Number of participants who achieved 100% reduction in complete weaning off (enteral autonomy) PS volume at EOS (up to Week 28) were reported.
| Participants | Teduglutide (TED) | Standard of Care (SOC) |
|---|---|---|
| Number of Participants Who Achieved 100 Percent (%) Reduction in Complete Weaning Off (Enteral Autonomy) Parenteral Support (PS) Volume at End of Study (EOS) | 0 | 0 |
Change from baseline in weight-normalized PS volume at EOT/ET (up to Week 24) was reported. EOT/ET was defined as the last available visit after the date of first dose (or randomization in standard of care treatment group) during the 24-week treatment period.
| mL/kg/day | Teduglutide (TED) | Standard of Care (SOC) |
|---|---|---|
| Diary Data: EOT/ET | -21.54 ± 28.909 | -9.51 ± 7.497 |
| Prescribed Data: EOT/ET | -22.90 ± 26.940 | -14.90 ± 12.323 |
Percent change from baseline in weight-normalized PS volume at EOT/ET (up to Week 24) was reported. EOT/ET was defined as the last available visit after the date of first dose (or randomization in standard of care treatment group) during the 24-week treatment period.
| Percent change | Teduglutide (TED) | Standard of Care (SOC) |
|---|---|---|
| Diary Data: EOT/ET | -24.77 ± 34.723 | -16.75 ± 16.392 |
| Prescribed Data: EOT/ET | -27.28 ± 33.518 | -22.39 ± 17.198 |
Change from baseline in weight-normalized PS caloric intake at EOT/ET (up to Week 24) were reported. EOT/ET was defined as the last available visit after the date of first dose (or randomization in standard of care treatment group) during the 24-week treatment period. Here, kilo-calories per kilogram per day was abbreviated as (kcal/kg/day).
| kcal/kg/day | Teduglutide (TED) | Standard of Care (SOC) |
|---|---|---|
| Diary Data: EOT/ET | -16.14 ± 17.547 | -6.10 ± 10.386 |
| Prescribed Data: EOT/ET | -15.31 ± 17.839 | -20.40 ± 21.024 |
Percent change from baseline in weight-normalized PS caloric intake at EOT/ET (up to Week 24) were reported. EOT/ET was defined as the last available visit after the date of first dose (or randomization in standard of care treatment group) during the 24-week treatment period.
| Percent change | Teduglutide (TED) | Standard of Care (SOC) |
|---|---|---|
| Diary Data: EOT/ET | -27.00 ± 29.473 | -13.68 ± 21.873 |
| Prescribed Data: EOT/ET | -27.81 ± 30.777 | -38.86 ± 39.893 |
Change from baseline in weight-normalized EN volume at EOT/ET (up to Week 24) was reported. EOT/ET was defined as the last available visit after the date of first dose (or randomization in standard of care treatment group) during the 24-week treatment period.
| mL/kg/day | Teduglutide (TED) | Standard of Care (SOC) |
|---|---|---|
| Diary Data: EOT/ET | 16.14 ± 18.683 | -15.25 ± 31.496 |
| Prescribed Data: EOT/ET | -1.28 ± 2.563 | 2.27 ± 22.232 |
Percent change from baseline in weight-normalized EN volume at EOT/ET (up to Week 24) was reported. EOT/ET was defined as the last available visit after the date of first dose (or randomization in standard of care treatment group) during the 24-week treatment period.
| Percent change | Teduglutide (TED) | Standard of Care (SOC) |
|---|---|---|
| Diary Data: EOT/ET | 273.20 ± 246.784 | -44.25 ± 78.847 |
| Prescribed Data: EOT/ET | -16.40 ± NA | 14.80 ± 69.834 |
Change from baseline in weight-normalized EN caloric intake at EOT/ET (up to Week 24) were reported. EOT/ET was defined as the last available visit after the date of first dose (or randomization in standard of care treatment group) during the 24-week treatment period.
| kcal/kg/day | Teduglutide (TED) | Standard of Care (SOC) |
|---|---|---|
| Diary Data: EOT/ET | 9.08 ± 10.662 | -9.38 ± 21.402 |
| Prescribed Data: EOT/ET | -1.15 ± 2.306 | 3.11 ± 16.285 |
Percent change from baseline in weight-normalized EN caloric intake at EOT/ET (up to Week 24) were reported. EOT/ET was defined as the last available visit after the date of first dose (or randomization in standard of care treatment group) during the 24-week treatment period.
| Percent change | Teduglutide (TED) | Standard of Care (SOC) |
|---|---|---|
| Diary Data: EOT/ET | 207.06 ± 153.159 | -44.25 ± 78.847 |
| Prescribed Data: EOT/ET | -16.40 ± NA | 24.18 ± 78.115 |
Number of participants who achieved at least 20% increase from baseline in weight-normalized EN volume at EOT/ET was reported. EOT/ET was defined as the last available visit after the date of first dose (or randomization in standard of care treatment group) during the 24-week treatment period.
| Participants | Teduglutide (TED) | Standard of Care (SOC) |
|---|---|---|
| Diary Data: EOT/ET | 2 | 0 |
| Prescribed Data: EOT/ET | 0 | 2 |
Number of participants who achieved at least 20% increase from baseline in weight-normalized EN caloric intake at EOT/ET was reported. EOT/ET was defined as the last available visit after the date of first dose (or randomization in standard of care treatment group) during the 24-week treatment period.
| Participants | Teduglutide (TED) | Standard of Care (SOC) |
|---|---|---|
| Diary Data: EOT/ET | 2 | 0 |
| Prescribed Data: EOT/ET | 0 | 2 |
Collected over From start of study treatment up to end of study (EOS) (up to Week 28). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Teduglutide (TED) | 0/5 (0%) | 4/5 (80%) | 5/5 (100%) |
| Standard of Care (SOC) | 0/5 (0%) | 3/5 (60%) | 5/5 (100%) |
| Event | Teduglutide (TED) | Standard of Care (SOC) |
|---|---|---|
| Device related infectionInfections and infestations | 0/5 | 2/5 |
| PyrexiaGeneral disorders | 1/5 | 0/5 |
| Immunisation reactionImmune system disorders | 1/5 | 0/5 |
| Transaminases increasedInvestigations | 0/5 | 1/5 |
| Metabolic acidosisMetabolism and nutrition disorders | 0/5 | 1/5 |
| AtaxiaNervous system disorders | 0/5 | 1/5 |
| Device breakageProduct Issues | 1/5 | 0/5 |
| Device leakageProduct Issues | 1/5 | 0/5 |
| Device occlusionProduct Issues | 0/5 | 1/5 |
| Event | Teduglutide (TED) | Standard of Care (SOC) |
|---|---|---|
| VomitingGastrointestinal disorders | 3/5 | 1/5 |
| DiarrhoeaGastrointestinal disorders | 2/5 | 0/5 |
| Frequent bowel movementsGastrointestinal disorders | 2/5 | 0/5 |
| TeethingGastrointestinal disorders | 0/5 | 2/5 |
| NasopharyngitisInfections and infestations | 2/5 | 0/5 |
| Upper respiratory tract infectionInfections and infestations | 1/5 | 2/5 |
| AnaemiaBlood and lymphatic system disorders | 1/5 | 0/5 |
| Iron deficiency anaemiaBlood and lymphatic system disorders | 1/5 | 0/5 |
| Abdominal discomfortGastrointestinal disorders | 1/5 | 0/5 |
| Abdominal distensionGastrointestinal disorders | 1/5 | 0/5 |
Safety set consisted of all participants who met the following criteria: Teduglutide treatment arm: participants who received at least 1 dose of teduglutide and had undergone at least 1 post baseline safety assessment; Standard of care treatment arm: participants who had undergone at least 1 post baseline safety assessment.
| Age, Continuous(Months) | Teduglutide (TED) | Standard of Care (SOC) | Total |
|---|---|---|---|
| Mean | 8.5 ± 3.09 | 8.3 ± 2.65 | 8.4 ± 2.71 |
| Sex: Female, Male(Participants) | Teduglutide (TED) | Standard of Care (SOC) | Total |
|---|---|---|---|
| Female | 1 | 2 | 3 |
| Male | 4 | 3 | 7 |
| Ethnicity (NIH/OMB)(Participants) | Teduglutide (TED) | Standard of Care (SOC) | Total |
|---|---|---|---|
| Hispanic or Latino | 0 | 0 | 0 |
| Not Hispanic or Latino | 5 | 5 | 10 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Teduglutide (TED) | Standard of Care (SOC) | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 1 | 1 | 2 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 0 |
| White | 4 | 4 | 8 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No — De-identified individual participant data from this particular study will not be shared as there is a reasonable likelihood that individual patients could be re-identified (due to the limited number of study participants/study sites, ...).
Ran from Aug 2018 to primary completion in Sep 2020, 24 months.
Results were first posted in Apr 2021, 6 months after primary completion.
Of 26 industry-sponsored phase 3 interventional studies under Short Bowel Syndrome, half reached primary completion within 36 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 45. This study's 24 months is below that.
Counting every sponsor, half of 27 studies reached it within 37 months; a quarter within 24 and three quarters within 46.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Teduglutide